# Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model

> **NCT03263663** · — · UNKNOWN · sponsor: **PD Dr. med. Volker Heinemann** · enrollment: 1000 (estimated)

## Conditions studied

- Colo-rectal Cancer
- RAS Wild-type
- UICC III
- UICC II + RF
- UICC IV Curative Intent

## Interventions

- **DRUG:** targeted substance according to the avatar model

## Key facts

- **NCT ID:** NCT03263663
- **Lead sponsor:** PD Dr. med. Volker Heinemann
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01-01
- **Primary completion:** 2021-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2017-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03263663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03263663, "Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03263663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*